(Q5138908)

Cobicistat (English)

3 October 2016

C₄₀H₅₃N₇O₅S₂

1 reference

Cobicistat (English)

19 November 2016

CC(C)C1=NC(=CS1)CN(C)C(=O)NC(CCN2CCOCC2)C(=O)NC(CCC(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5

1 reference

Cobicistat (English)

19 November 2016

CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5

1 reference

https://www.whocc.no/atc_ddd_index/?code=V03AX03

Cobicistat (English)

19 November 2016

0.15 gram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

cobicistat (English)

1 reference

cobicistat (English)

significant drug interaction

3 October 2016

domperidone

long QT syndrome

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ergotamine

ergotism

1 reference

A reference set of clinically relevant adverse drug-drug interactions

alfentanil

central respiratory depression

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sildenafil

hypotension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sildenafil

visual impairment

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sildenafil

priapism

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nifedipine

sinus bradycardia

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nifedipine

hypotension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nifedipine

acute kidney injury

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nimodipine

hypotension

1 reference

A reference set of clinically relevant adverse drug-drug interactions

simvastatin

rhabdomyolysis

1 reference

A reference set of clinically relevant adverse drug-drug interactions

simvastatin

muscular disease

1 reference

A reference set of clinically relevant adverse drug-drug interactions

atorvastatin

muscular disease

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sufentanil

central respiratory depression

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eliglustat

long QT syndrome

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rifabutin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

carbamazepin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pulseless electrical activity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

cardiotoxicity

1 reference

A reference set of clinically relevant adverse drug-drug interactions

subject has role

xenobiotic-transporting ATPase inhibitor

1 reference

5 March 2018

cytochrome P-450 CYP3A inhibitors

1 reference

CAS COVID-19 Anti-Viral Candidate Compounds

Medical Subject Headings

15 March 2018

1 reference

Medical Subject Headings

15 March 2018

Cobicistat

0 references

catalog

0 references

Identifiers

InChI

InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1

1 reference

Cobicistat (English)

19 November 2016

2 references

Cobicistat (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

1004316-88-4

2 references

cobicistat (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=1004316-88-4

9 April 2021

1 reference

Cobicistat (English)

19 November 2016

2 references

Cobicistat (English)

19 November 2016

Reaxys registry number

13088386

1 reference

cobicistat (English)

3 October 2016

mapping relation type

2 references

COBICISTAT (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C40H53N7O5S2/c1-29(2)38-43-34(27-53-38)25-46(3)39(49)45-36(16-17-47-18-20-51-21-19-47)37(48)42-32(22-30-10-6-4-7-11-30)14-15-33(23-31-12-8-5-9-13-31)44-40(50)52-26-35-24-41-28-54-35/h4-13,24,27-29,32-33,36H,14-23,25-26H2,1-3H3,(H,42,48)(H,44,50)(H,45,49)/t32-,33-,36+/m1/s1

1 reference

COBICISTAT (English)

19 November 2016

2 references

inferred from InChIKey

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

1 reference

2 references

DSSTOX compound identifier

0 references

1 reference

Guide to Pharmacology Ligand ID

Cobicistat (English)

publication date

17 November 2015

7535

2 references

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

7535

https://www.guidetopharmacology.org/coronavirus.jsp

cobicistat (English)

19 November 2016

22 April 2020

MeSH descriptor ID

D000069547

subject named as

Cobicistat

0 references

0 references

0 references

0 references

1 reference

cobicistat (English)

19 November 2016

1 reference

2 references

cobicistat (English)

19 November 2016

MedlinePlus drug identifier

0 references

1 reference

cobicistat (English)

19 November 2016

0 references

1 reference

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

Cobicistat (English)

19 January 2016

0 references

Microsoft Academic ID

0 references

1 reference

26 January 2022

UMLS CUI

C3177235

1 reference